Research programme: dengue virus vaccine - Cyto Pulse/WRAIR

Drug Profile

Research programme: dengue virus vaccine - Cyto Pulse/WRAIR

Alternative Names: Dengue virus vaccine research programme - Cyto Pulse/WRAIR

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cyto Pulse Sciences; Walter Reed Army Institute of Research
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Dengue

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Dengue in USA (Injection)
  • 16 Aug 2006 Cyto Pulse has been awarded a $US2 million grant from the US NIH for the development of a DNA vaccine against Flaviviruses and DNA vaccine delivery system
  • 26 Sep 2005 Preclinical trials in Dengue in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top